VLA4-Targeted PET Imaging for Accurate Bone Marrow Malignancy Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PET imaging techniques, such as FDG-PET, face limitations in accurately imaging multiple myeloma due to inconsistent glucose transporter expression and tumor microenvironment variability, leading to over- or under-estimation of disease burden in bone marrow.
Innovation Solution
Development of a VLA4-targeted PET imaging agent, [64Cu]Cu-LLP2A, which preferentially binds to activated VLA4 in bone marrow malignancies, allowing for precise imaging and monitoring of lesions, relapse, and treatment selection by modulating VLA4 expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If FDG-PET imaging is used for multiple myeloma, then imaging availability and ease of operation are improved, but measurement precision deteriorates due to inconsistent GLUT-1 and hexokinase-2 expression
Solution Approach 1:
The patent changes the imaging parameter from glucose metabolism (FDG) to VLA4 expression levels, using a different molecular target that is consistently expressed in multiple myeloma cells. This parameter change resolves the contradiction by selecting a marker with stable expression patterns rather than relying on metabolically variable markers like GLUT-1 and hexokinase-2.
Solution Approach 2:
The patent replaces the metabolic imaging mechanism (FDG uptake based on glucose metabolism) with a molecular targeting mechanism (VLA4 antibody-based imaging). This substitution moves from indirect metabolic assessment to direct molecular marker detection, improving precision while maintaining operational feasibility through PET imaging infrastructure.
2Adaptability or versatility
If FDG-PET imaging is used for multiple myeloma, then imaging accessibility is improved, but reliability deteriorates due to tumor microenvironment variability and inflammatory interference
Solution Approach 1:
The patent extracts the imaging specificity from the general metabolic signal and focuses it on a particular molecular target (VLA4) that is characteristically expressed on multiple myeloma cells. By taking out the focus from non-specific metabolic activity to specific molecular marking, the reliability of signal accuracy is improved while maintaining accessibility through standard PET infrastructure.
Solution Approach 2:
The patent introduces VLA4 expression as an intermediary marker between the tumor cells and the imaging signal. This intermediary molecular target provides a stable and specific bridge that connects the imaging system to the disease state, filtering out the interference from inflammatory microenvironment factors that plague direct metabolic imaging.
3Measurement precision
If VLA4-targeted imaging agent is developed, then measurement precision is improved for lesion identification, but device complexity increases
Solution Approach 1:
The patent segments the imaging agent into distinct functional components: the VLA4-targeting antibody portion and the radionuclide binding structure. This segmentation allows each component to be optimized independently for its specific function while maintaining overall simplicity in the conjugate design, achieving high measurement precision without excessive complexity.
Data Source
AI summary
Compositions, methods of synthesis, and methods of use for an imaging agent that preferentially binds to activated VLA4, including, but not limited to a peptide or peptidomimetic ligand radiolabeled for use in PET imaging to identify bone marrow malignancies, help select treatments for bone marrow malignancies, and monitor relapse in bone marrow malignancy patients after therapy are disclosed.